title: Human vascular adhesion proteın-1 (VAP-1): serum levels for hepatocellular carcinoma in non-alcoholic and alcoholic fatty liver disease.
abstract: BACKGROUND
  The incidence of hepatocellular cancer in complicated alcoholic and non-alcoholic fatty liver diseases is on the rise in western countries as well in our country. Vascular adhesion protein-1 (VAP-1) levels have been presented as new marker. In our study protocol, we assessed the value of this serum protein, as a newly postulant biomarker for hepatocellular cancer in patients with a history of alcoholic and non-alcoholic fatty liver diseases.
  
  
  METHODS
  Pre-operative serum samples from 55 patients with hepatocellular cancer with a history of alcoholic and non-alcoholic fatty liver diseases and patients with cirrhosis were assessed by a quantitative sandwich ELISA using anti-VAP-1 mAbs. This technique is used to determine the levels of soluble VAP-1 (sVAP-1) in the serum.
  
  
  RESULTS
  sVAP-1 levels were evaluated in patients with hepatocellular cancer and liver cirrhosis. There was a significant difference in mean VAP-1 levels between groups. Serum VAP-1 levels were found higher in patients with hepatocellular cancer.
  
  
  CONCLUSIONS
  These findings indicate that the serum level of sVAP-1 might be a beneficial marker of disease activity in chronic liver diseases.
authors.affiliation: Department of General Surgery, Yuzuncu Yil University Medical Faculty, Van, Turkey. ozgurkemik@hotmail.com
authors.forename: Ozgur
authors.initials: O
authors.lastname: Kemik
authors.forename: Aziz
authors.initials: A
authors.lastname: Sümer
authors.forename: Ahu Sarbay
authors.initials: AS
authors.lastname: Kemik
authors.forename: Veyis
authors.initials: V
authors.lastname: Itik
authors.forename: Ahmet Cumhur
authors.initials: AC
authors.lastname: Dulger
authors.forename: Sevim
authors.initials: S
authors.lastname: Purisa
authors.forename: Sefa
authors.initials: S
authors.lastname: Tuzun
mesh_terms: D006631:Amine Oxidase (Copper-Containing) / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood; D006528:Carcinoma, Hepatocellular / Q000097:blood* / Q000175:diagnosis / Q000209:etiology; D015815:Cell Adhesion Molecules / Q000097:blood*; D018450:Disease Progression; D004797:Enzyme-Linked Immunosorbent Assay; D005234:Fatty Liver / Q000097:blood / Q000150:complications / Q000175:diagnosis; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008113:Liver Neoplasms / Q000097:blood* / Q000175:diagnosis / Q000209:etiology; D008297:Male; D008875:Middle Aged; D065626:Non-alcoholic Fatty Liver Disease; D011379:Prognosis; D012795:Sialoglycoproteins
chemical_list: D014408:Biomarkers, Tumor; D015815:Cell Adhesion Molecules; D012795:Sialoglycoproteins; C076668:AOC3 protein, human; D006631:Amine Oxidase (Copper-Containing)